MS and Demyelinating Disorders

The neurologist at Allegheny Health Network’s Neuroscience Institute provided perspective on a new phase 3 trial assessing fenebrutinib, an investigational BTK inhibitor for relapsing multiple sclerosis.

The 2022 Congress of the European Committee for Treatment and Research in Multiple Sclerosis will take place in Amsterdam, the Netherlands, from October 26 to 28, and is expected to feature almost 250 presenters.

The neurologist at the Corinne Goldsmith Dickinson Center for MS offered a brief overview of his experience at the 2022 IFN conference held in New York City on September 23-24. [WATCH TIME: 4 minutes]

Permanent disability, found in 51% of patients with NMOSD at follow-up, was attributed mainly to age of disease onset, delay in diagnosis, and initial EDSS score.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 21, 2022.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Stephen Krieger, MD; Richard Isaacson, MD; and Jessica Ailani, MD. [LISTEN TIME: 24 minutes]

A cross-sectional study showed that retinal measurements in patients with “potential” neuromyelitis optica spectrum disorder were similar to those with definite neuromyelitis optica spectrum disorder.

Chaired by Robert T. Naismith, MD, this NeurologyLive® State of the Science Summit will be held virtually at 6:30 PM CST on November 3, 2022. Register for free now!

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

A report on two patients with late-onset neutropenia resulted in an uncommon adverse event following anti-CD20 therapies.

P100 amplitude of 15 minute checks in the NMOSD-ON group had a significant reduction at 6 months relative to the IDON group, suggesting more several axonal damage.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 14, 2022.

Annualized relapse rates were elevated compared with the prepregnancy period, especially during the initial 3 months after delivery, whereas EDSS scores worsened during pregnancy and the postpartum period.

New data from the NOVA trial showed differences in the number of T2 lesions in patients with relapsing-remitting multiple sclerosis at 72 weeks of treatment with natalizumab (Tysabri; Biogen), though seemingly driven by data from only 2 participants with extreme new or newly enlarging T2 hyperintense lesion numbers.

A study using patient data from John Hopkins showed that rituximab treatment was associated with reduced annualized relapse rates in AQP4-IgG seropositive NMOSD and MOGAD.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is insomnia.

Data from a MSbase registry on patients with multiple sclerosis show in its findings that the incorporation of the Multiple Sclerosis Severity Score improved the prediction accuracy of relapses in MS.

Using magnetic resonance spectroscopy, investigators observed significantly different levels of total NAA across MS and NMOSD subtypes, and a negative correlation between total NAA and disability score.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 7, 2022.

Expert clinicians offer their perspectives on developmental milestones for children, the NMSOD patient perspective, effective treatments for insomnia, ALS, diabetic and inflammatory neuropathies, and lecanemab in early Alzheimer disease.

The RNDS, created to bring together those with rare neuroimmune disorders and clinical community together, is a 3-day hybrid educational event held October 7-9 in Los Angeles, California